Optogenetics has become an emerging technique for neuroscience investigations owing to the great spatiotemporal precision and the target selectivity it provides. Here we extend the optogenetic strategy to GABA A receptors (GABA A Rs), the major mediators of inhibitory neurotransmission in the brain. We generated a light-regulated GABA A receptor (LiGABAR) by conjugating a photoswitchable tethered ligand (PTL) onto a mutant receptor containing the cysteine-substituted α1-subunit. The installed PTL can be advanced to or retracted from the GABA-binding pocket with 500 and 380 nm light, respectively, resulting in photoswitchable receptor antagonism. In hippocampal neurons, this LiGABAR enabled a robust photoregulation of inhibitory postsynaptic currents. Moreover, it allowed reversible photocontrol over neuron excitation in response to presynaptic stimulation. LiGABAR thus provides a powerful means for functional and mechanistic investigations of GABA A R-mediated neural inhibition.
O ptogenetics, an integrated strategy that typically employs microbial opsins to overpower neuronal excitability, has become a revolutionary technique for neuroscience investigations. 1 This technique enables light to remotely manipulate neuronal activity with high spatial and temporal precision. Moreover, it allows photocontrol over a defined neuron type within an intact tissue or even a behaving organism. 1 However, microbial opsins are functionally distinct from neuronal signaling proteins (e.g., neurotransmitter receptors for synaptic transmission) and hence are constrained to decode neural circuits at the cellular level. To gain molecular insights into neural functions, methods that allow optogenetic control over a specific signaling mediator are highly desired. 2 Here we present a chemical-genetic approach that enables photocontrol over inhibitory neurotransmission mediated by the ionotropic type-A GABA receptors (GABA A Rs). Our approach allows light to specifically modulate a defined subtype of GABA A R, which will help elucidate the unique functions of the receptor within a complex neural network.
The GABA A Rs, a group of neurotransmitter-gated chloridepermeable channels, are therapeutic targets in psychiatric disorders 3 and epilepsy 4 owing to their inhibitory control over neuronal excitation. They are also targets for many drugs of abuse, including alcohol, barbiturates, and benzodiazepines. 3, 5, 6 The GABA A Rs are heteropentameric assemblies composed of two α, two β, and one tertiary subunit (usually γ or δ, Figure 1a ). 3, 5 Among these components, the α-subunit is key in determining receptor localization and gating kinetics 3, 5, 7, 8 and, together with the β subunit, forms the GABA-binding site. 3 There are six distinct α-isoforms expressed heterogeneously in different neuron types and brain regions. 3, 5, 6 Adding to this complexity, a neuron can express multiple αisoforms that are differentially distributed in subcellular compartments. 7 These findings suggest that each α-isoform has unique roles in neuronal signaling, and understanding their individual functions will provide key insights into GABA A Rassociated disorders and therapeutics.
We have engineered a light-regulated GABA A receptor (LiGABAR) by covalently conjugating a photoswitchable tethered ligand (PTL) onto a receptor containing the cysteine-substituted α-subunits ( Figure 1a ). The PTL comprises a sulfhydryl-reactive maleimide group, a photoswitchable azobenzene core, and a ligand for the GABA-binding site ( Figure 1b ). It reversibly isomerizes between cis (twisted) and trans (extended) configurations upon the illumination of 380 and 500 nm light, respectively. Once installed near the GABAbinding pocket, the PTL can retract or advance its ligand via photoisomerization, leading to reversible photocontrol of the receptor activity. The wild-type GABA A Rs display very few extracellular cysteines which are either involved in disulfide formation or are distant from the GABA-binding site. Hence, the PTL will exert its function only on an engineered receptor with appropriately positioned cysteines, ensuring the target specificity of photocontrol within a heterogeneous population of GABA A Rs.
Our prototype PTL was designed based on previously published GABA A R probes in which the pharmacophore muscimol is conjugated to a fluorophore or biotin via a 6aminohexanoyl spacer. 9 The resulting PTL, named MAM-6, comprises a maleimide, an azobenzene, and a muscimol linked through a 6-carbon spacer ( Figure 1b ). Although muscimol can work as a photoaffinity probe for GABA A Rs, 10 the wavelengths for MAM-6 photoisomerization are >100 nm longer than that for muscimol photolysis and are thus incapable of triggering this side reaction. We screened MAM-6 attachment sites for the α1-containing GABA A R, the most abundant α-isoform in the brain. The screening was carried out in Xenopus oocytes expressing the engineered receptors. Residues that are predicted to face the GABA-binding site were chosen for cysteine substitution (Figure 1c ). Previous studies suggested that cysteine substitutions at these locations allow the mutant receptors to express normally and remain sensitive to GABA and allosteric modulators (e.g., pentobarbital and benzodiazepines). 11, 12 These mutants are thus ideal candidates for MAM-6 conjugation.
Although muscimol is ordinarily an agonist for GABA A Rs, the mutant receptors were not activated by either 380 or 500 nm light after MAM-6 conjugation. Instead, MAM-6 inhibited some of the mutant receptors in a light-dependent manner, with 500 nm (trans MAM-6) causing a greater decrement in GABA-elicited current than 380 nm (cis MAM-6) did ( Figure  1d and e and Supplementary Figure S1 ). This phenomenon, i.e., photoswitchable antagonism mediated by an agonist-based PTL, is similar to an observation reported previously for the nicotinic acetylcholine receptors, 13 possibly caused by the PTL disrupting conformational changes required for receptor activation. 13, 14 To quantitatively evaluate each attachment site, we indexed receptor photosensitivity as the ratio of GABA-elicited current in 380 nm vs in 500 nm (I 380 /I 500 ). MAM-6 caused a strong photoregulation when attached at sites closer to the entrance of the GABA-binding pocket (Figure 1c and e). We selected α1(T125C) as optimal because it allows MAM-6 to substantially inhibit the receptor in 500 nm while allowing the receptor to function normally in 380 nm ( Supplementary Table S1 and Figure S1 ). Moreover, cysteine substitution at this location does not alter the receptor's GABA sensitivity (ref 11 and Supplementary Table S1 ). These properties make α1(T125C) and its resulting LiGABAR preferable for neurophysiological investigations.
We next focused on α1(T125C) and investigated the structural requirements for a PTL to operate at this conjugation site. We changed the ligand and spacer moieties of MAM-6 and indexed the photoregulation effects in HEK293T cells (at 10 μM GABA; Figure 2a ). The negative charge of muscimol (at physiological pH) is involved in receptor binding. Consistent with this mechanism, replacing muscimol with a neutral analogue 4-hydroxybenzylamine reduced the photoregulation effect (I 380 /I 500 = 2.5 ± 0.3 and 1.7 ± 0.1, n = 6 and 3 for MAM-6 and MAB-6, respectively; Figure 2a ). Removing the 6carbon spacer of MAM-6 suppressed photoregulation nearly completely (MAM-0; I 380 /I 500 = 1.3 ± 0.1, n = 4; Figure 2a ), suggesting that this spacer is important for delivering muscimol into the GABA-binding pocket. Surprisingly, substituting muscimol with 4-hydroxybenzylamine in MAM-0 boosted photoregulation, giving an effect greater than that by MAM-6 (MAB-0; I 380 /I 500 = 3.4 ± 0.4, n = 7; Figure 2a ). The strong photoregulation by MAB-0 suggests a favorable interaction between its ligand moiety and the GABA-binding pocket that is specific for the trans configuration. The GABAbinding pocket is lined by several aromatic residues (i.e., the aromatic box), 14, 15 and these residues may interact with 4hydroxybenzylamide, enabling it to compete with GABA. This hypothesis was further supported by the docking of trans MAB-0 in a homology model. The result suggested that trans MAB-0 spans the distance between the attachment site and the binding pocket, delivering its terminal phenol group to the aromatic box ( Figure 2b) . Trans-to-cis isomerization allows the PTL to twist, which withdraws the ligand and subsequently relieves receptor antagonism. Consistent with this working model, the EC 50 of this LiGABAR increased 8-fold when the light was switched from 380 to 500 nm (10.2 ± 2.6 μM and 84.0 ± 19.3 μM, respectively, n = 4 for each; Figure 2c ). In addition, the EC 50 of the conjugated receptor in 380 nm light was the same as that of the wild-type (11.4 ± 2.2 μM, n = 3; Figure 2c ). This LiGABAR thus provides an ideal system in which the receptor can be reversibly switched between normal and inhibited states by two different wavelengths of light. These findings also suggest that a typical agonist/antagonist is not mandatory for an effective PTL. When the scaffold is tethered at an appropriate position, a molecule that potentially interacts with the GABA-binding pocket could be a potent ligand, which opens a door for future PTL design. Moreover, because the GABA-binding site is highly homologous among the GABA A R family, this strategy may be applicable to other α-isoforms to expand the toolkit.
Cis-to-trans isomerization of azobenzenes can be driven by 500 nm light or will occur spontaneously in darkness through thermal relaxation (Figure 1b and ref 16 ). The rate of thermal relaxation for a cis azobenzene is dependent on its chemical structure and the local environment. 16 Thermal relaxation of MAB-0 (tethered to α1(T125C)) was measured by a functional assay illustrated in Figure 3 . GABA-elicited current was measured in HEK293T cells every 2 min in darkness after an initial response under 5 s of 380 nm illumination. The current decreased slowly during the dark period but was fully restored by a subsequent illumination of 380 nm light, suggesting that the observed current reduction arose from thermal relaxation of cis MAB-0 ( Figure 3a) . We plotted the normalized lightsensitive current over time and fitted the data with a singleexponential decay (Figure 3b ). The half-life of cis MAB-0 was calculated to be 23.6 ± 2.7 min (n = 5) in darkness. The slow thermal relaxation of cis PTL makes LiGABAR bistable, allowing the receptor to stay in the uninhibited state for minutes after a brief pulse of 380 nm light. This feature provides a way to minimize possible adverse effects of light during the course of an experiment.
The α1-GABA A R is known to cluster at the inhibitory synapse, 7 where it detects GABA released from the presynaptic axon terminal and mediates transient postsynaptic responses. 17, 18 GABA is released into the synaptic cleft through vesicle exocytosis either spontaneously (which elicits miniature inhibitory postsynaptic current, mIPSC) or driven by action potential. 17 To test whether LiGABAR enables photocontrol over synaptic inhibition, we measured the photosensitivity of mIPSCs in LiGABAR-containing neurons. Cultured hippocampal neurons were transfected with a bicistronic construct encoding α1(T125C) and an expression marker (eGFP). The cells were subsequently treated with MAB-0 to generate LiGABARs in situ. As shown in Figure 4a , the amplitude of mIPSCs in a LiGABAR-containing neuron increased within 5 s of exposure to 380 nm light and remained elevated in darkness for at least 2 min, consistent with the slow thermal relaxation of cis MAB-0 measured in Figure 3 . The amplitude of mIPSCs decreased again upon exposure to 500 nm light. To quantify photosensitivity, we calculated the average mIPSC when MAB-0 was in either trans or cis configuration (Figure 4b) . Cis-totrans photoisomerization caused a 38 ± 2% decrease in the peak amplitude and a 57 ± 4% decrease in the total charge transfer (n = 6; Figure 4b and c). The robust photocontrol over mIPSCs validates the applicability of LiGABAR for neurophysiological investigations.
LiGABAR is developed for specifically probing a defined GABA A R subtype within a complex neural system. Efficacious PTL performance should occur only when the receptor possesses the engineered subunit. Consistent with our design principle, MAB-0 treatment did not confer detectable photosensitivity onto wild-type GABA A Rs (Supplementary Figure  S2) . Likewise, MAB-0 treatment did not photosensitize ionotropic glutamate receptors or voltage-gated channels in neurons (Supplementary Figure S2) . All together, our results suggest that light can specifically modulate the inhibitory responses mediated by the engineered GABA A R with no apparent off-target effects.
Finally, we examined how the manipulation of LiGABAR alters neuronal excitation. Native GABA A Rs play a crucial role in preventing runaway excitation in the brain. Pharmacological blockade of GABA A Rs 19, 20 or mutations that alter GABA A R functions 4 can result in epilepsy. Accordingly, we tested whether epileptiform activity can be induced by photoantagonizing LiGABAR in an intact, ex vivo preparation. To express the mutant subunit, we infected a hippocampal slice with an adeno-associated virus encoding α1(T125C) and an eGFP marker. After treating the slice with MAB-0, we applied a train of electrical pulses to stimulate presynaptic inputs and recorded the postsynaptic potential in 380 or 500 nm light. As shown in Figure 4d , the presynaptic stimulation triggered a series of postsynaptic action potentials in 380 nm light. When LiGABAR was antagonized with 500 nm light, the spike train culminated in a plateau potential that is characteristic of epileptiform activity. 21 Switching light back to 380 nm eliminated the effect, demonstrating the reversibility of LiGABAR modulation. This result suggests that optical perturbation of LiGABAR function is sufficient to cause a profound impact on neuronal excitation.
In summary, our approach enables light to manipulate the inhibitory events mediated by a designated subtype of GABA A R. LiGABAR inherits two renowned benefits from opsin-based optogenetics, namely, the fine spatiotemporal precision of optical control and the capability of targeted gene expression using cell-type specific promoters. 1,2 PTL photoisomerization can alter neuronal activity within milliseconds reversibly and reliably, 22 suitable for accurate neurophysiological manipulations. Aside from these advantages, LiGABAR differs from microbial opsins in that it allows direct photocontrol over a genuine mediator in neuronal signaling. GABA A Rs mediate inhibitory neurotransmission in the nervous system, with different subtypes exerting distinct biophysical properties and cellular/subcellular distributions. 3, 5, 7, 8 The biochemical specificity of photocontrol makes LiGABAR favorable for probing the function/distribution of a GABA A R subtype within a neuron or a neural circuit. Compared to diffusible caged agonists or photochromic modulators (i.e., optopharmacology), 2 the use of LiGABAR is more technically demanding due to the requirement of two exogenous components (mutant subunit and PTL). However, LiGABAR enables advanced investigations that aim to explore a specific receptor and/or neuron subtype in a complex system, which cannot be achieved with existing optopharmacology agents because of their lack of target specificity. 2 LiGABAR thus presents a unique opportunity for understanding the mechanisms of neural inhibition, and will ultimately provide new insights into brain function and dysfunction. Quantification of mIPSC photoregulation (mean ± SEM) as the percent decrease when MAB-0 was switched from cis to trans. The total charge transfer was measured by integrating the area of average mIPSC. 17 (d) Photocontrol over neuronal excitation in a hippocampal slice. Current-clamp recording was carried out in a LiGABARcontaining CA1 pyramidal neuron. Illumination by 500 nm light resulted in an "epileptic" plateau potential that was subsequently eliminated by 380 nm light.
Receptor Expression and PTL Treatment. Xenopus Oocytes. RNA was prepared with the mMessage mMachine T7 kit (Ambion). Defolliculated Xenopus oocytes were injected with 2.5−20 ng of mRNA in 50 nL of H 2 O in a ratio of 1:1 (α1:β2). The injected oocytes were incubated at 18°C (in ORI buffer) and subjected to twoelectrode voltage-clamp recording 1−3 days after RNA injection. To screen MAM-6 attachment sites, oocytes expressing each mutant receptor were incubated with 50 μM MAM-6 for 0.5−1.5 h prior to recording.
HEK293T Cells. Cells were maintained in Dulbecco's Minimum Essential Medium (Gibco) supplemented with 10% fetal bovine serum (Gibco) at 37°C and 5% CO 2 . Cells were plated at 18−24 × 10 3 cells/cm 2 on poly-L-lysine-coated coverslips and were transfected via calcium phosphate precipitation. A total of 1.1 μg of DNA per coverslip (α:β:γ:eGFP = 0.15:0.15:0.75:0.05) was used. Recordings were carried out 36−48 h after transfection. Prior to recording, cells (in extracellular recording solution) were treated with dithiothreitol (DTT; 3 mM, 5 min), incubated in fresh extracellular recording solution (5 min), and then treated with PTL (25 μM, 20 min) at RT in the dark.
Cultured Hippocampal Neurons. Primary cultures of neonatal rat hippocampal neurons were prepared and maintained following previously described procedures. 23 Neurons were transfected via calcium phosphate precipitation (1.2 μg of the bicistronic pAAV construct per well) 6−8 days after preparation. Recordings were carried out 1−2 weeks after transfection. Prior to recording, neurons (in extracellular recording solution) were treated with tris(2carboxyethyl)phosphine (TCEP; 5 mM, 5 min), incubated in fresh extracellular recording solution (5 min), and then treated with MAB-0 (25 μM, 20 min) at RT in the dark.
Organotypic Slice Cultures. Sprague−Dawley rat pups (postnatal day 8) were anaesthetized and decapitated. Hippocampi were removed and sliced into 350-μm-thick sections. Slices were maintained at 34°C on cell culture inserts in Neurobasal-A medium (Invitrogen) supplemented with 20% horse serum (Thermo Scientific), 0.03 units/mL insulin (Sigma), 0.5 mM ascorbic acid (Sigma), 1X Gluta-Max (Life Technologies), 80 units/mL penicillin (Life Technologies), 80 μg/mL streptomycin (Life Technologies), and 25 mM HEPES. One day after preparation, slices were injected with AAV9 (7.5 × 10 12 vg/mL) encoding the bicistronic construct of eGFP-2A-α1(T125C). The CA1 pyramidal cell body layer was injected at 3−7 sites/slice with 100 nL of virus. Recordings were carried out 5−14 days postinjection. Prior to recording, slices were incubated for 2 min with 1 mM TCEP in artificial cerebrospinal fluid (ACSF), washed, and incubated with 25 μM MAB-0 in ACSF for 30 min at RT.
